Alkem Laboratories Limited — Gliclazide Exporter Profile
Indian Pharmaceutical Exporter · #14 for Gliclazide · $2.0M export value · DGFT Verified
Alkem Laboratories Limited is the #14 Indian exporter of Gliclazide with $2.0M in export value and 68 verified shipments. Alkem Laboratories Limited holds a 0.7% market share in Gliclazide exports across 2 countries. The company exports 30 pharmaceutical products worth $247.0M across 15 therapeutic categories.
Alkem Laboratories Limited — Gliclazide Export Profile: Buyers & Destinations
Where Does Alkem Laboratories Limited Export Gliclazide?
| Country | Value | Shipments | Share |
|---|---|---|---|
| AUSTRALIA | $1.8M | 67 | 99.8% |
| CHILE | $2.8K | 1 | 0.2% |
Alkem Laboratories Limited exports Gliclazide to 2 countries. The largest destination is AUSTRALIA accounting for 99.8% of Alkem Laboratories Limited's Gliclazide shipments. These destinations reflect Alkem Laboratories Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Gliclazide from Alkem Laboratories Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| PHARMACOR PTY LTD | AUSTRALIA | $1.0M | 39 |
| PHARMACOR PTY LTD, | AUSTRALIA | $327.7K | 13 |
| PHARMACOR PTY LTD.,. | AUSTRALIA | $322.0K | 9 |
| PHARMACOR PTY LIMITED | AUSTRALIA | $112.1K | 6 |
| ASCEND LABORATORIES SPA | CHILE | $2.8K | 1 |
Alkem Laboratories Limited supplies Gliclazide to 5 buyers globally. The largest buyer is PHARMACOR PTY LTD (AUSTRALIA), followed by PHARMACOR PTY LTD, (AUSTRALIA) and PHARMACOR PTY LTD.,. (AUSTRALIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Gliclazide Export Value and How Much Does Alkem Laboratories Limited Contribute?
India exported $68.5M worth of Gliclazide through 3,830 shipments from 238 suppliers to 109 countries, serving 643 buyers globally. Alkem Laboratories Limited contributes $2.0M to this total, accounting for 0.7% of India's Gliclazide exports. Alkem Laboratories Limited ships Gliclazide to 2 countries through 5 buyers.
What Is the Average Shipment Value for Alkem Laboratories Limited's Gliclazide Exports?
Alkem Laboratories Limited's average Gliclazide shipment value is $29.2K per consignment, based on 68 shipments totaling $2.0M. The largest destination is AUSTRALIA (99.8% of Alkem Laboratories Limited's Gliclazide exports).
How Does Alkem Laboratories Limited Compare to Other Indian Gliclazide Exporters?
Alkem Laboratories Limited ranks #14 among 238 Indian Gliclazide exporters with a 0.7% market share. The top 3 exporters are SUN PHARMACEUTICAL INDUSTRIES LIMITED ($15.1M), MICRO LABS LIMITED ($7.6M), IPCA LABORATORIES LIMITED ($7.3M). Alkem Laboratories Limited processed 68 shipments to 2 destination countries.
What Gliclazide Formulations Does Alkem Laboratories Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMACEUTICAL PRODUCTS :PHARMACOR GLICLAZIDE MR 60 MG 6X10'S AU | $292.4K | 9 |
| PHARMACEUTICAL PRODUCTS : PHARMACOR GLICLAZIDE MR 60 MG 60'S HDPE | $215.2K | 9 |
| PHARMACOR GLICLAZIDE MR 60 MG 6 X 10S A | $190.9K | 5 |
| PHARMACEUTICAL PRODUCTS PHARMACOR GLICLAZIDE MR 60 MG 6X10'S AU | $150.0K | 3 |
| PHARMACOR GLICLAZIDE MR 60 MG 6X10'S AU | $133.7K | 4 |
| PHARMACEUTICAL PRODUCTS : PHARMACOR GLICLAZIDE MR 60 MG 6X10'S AU | $111.9K | 3 |
| PHARMACOR GLICLAZIDE MR 60 MG 6X10 S AU | $100.0K | 2 |
| PHARMACOR GLICLAZIDE MR 60 MG 60S HDPE.PCS | $97.8K | 4 |
| PHARMACEUTICAL PRODUCTS :PHARMACOR GLICLAZIDE MR 60 MG 60'S HDPE | $90.8K | 4 |
| PHARMACOR GLICLAZIDE MR 60 MG 60S HDPE | $57.1K | 4 |
Alkem Laboratories Limited exports 26 distinct Gliclazide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMACEUTICAL PRODUCTS :PHARMACOR GLICLAZIDE MR 60 MG 6X10' with 9 shipments worth $292.4K.
Regulatory Requirements: Exporting Gliclazide to Key Markets
What Alkem Laboratories Limited must comply with to export Gliclazide to its top destination countries
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Alkem Laboratories Limited Compare to Nearest Gliclazide Exporters?
Exporters ranked immediately above and below #14 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | PANACEA BIOTEC PHARMA LIMITED | $2.5M | 50 | 5 | $50.0K |
| 13 | INVENTIA HEALTHCARE LIMITED | $2.0M | 134 | 6 | $14.8K |
| 14 | ALKEM LABORATORIES LIMITED ★ | $2.0M | 68 | 2 | $29.2K |
| 12 | CENTAUR PHARMACEUTICALS PRIVATE LIMITED | $1.8M | 36 | 9 | $50.0K |
| 15 | WALLACE PHARMACEUTICALS PRIVATE LIMITED | $1.1M | 22 | 1 | $50.0K |
Alkem Laboratories Limited ranks #14 among 238 Indian Gliclazide exporters. Average shipment value of $29.2K compared to the market average of $287.6K. The closest competitors by value are PANACEA BIOTEC PHARMA LIMITED and INVENTIA HEALTHCARE LIMITED.
Which Indian Ports Ship Gliclazide Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 439 | 11.5% |
| SAHAR AIR | 375 | 9.8% |
| JNPT/ NHAVA SHEVA SEA | 323 | 8.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 247 | 6.4% |
| DELHI AIR | 229 | 6.0% |
| JNPT | 203 | 5.3% |
| DELHI AIR CARGO ACC (INDEL4) | 165 | 4.3% |
| CMA CGM LOGISTICS PARK ICD | 103 | 2.7% |
Geopolitical & Trade Policy Impact on Alkem Laboratories Limited's Gliclazide Exports
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like Alkem Laboratories. Escalating tensions in the Red Sea region, particularly due to Houthi attacks, have disrupted traditional shipping routes, leading to increased freight costs and extended delivery timelines. Major carriers have rerouted vessels around the Cape of Good Hope, adding 10–20 days to transit times and raising freight rates by 40–50% on key India–Europe routes (livemint.com). This logistical upheaval necessitates strategic adjustments in supply chain management to mitigate delays and cost escalations.
Conversely, the ongoing US-China trade tensions have prompted the United States to diversify its pharmaceutical supply sources, potentially benefiting Indian exporters. Alkem's established presence in the US market positions it to capitalize on this shift, provided it maintains stringent compliance with US regulatory standards. Additionally, the recent India–European Union Free Trade Agreement, signed in January 2026, aims to eliminate tariffs on pharmaceuticals, enhancing the competitiveness of Indian exporters in the EU market (en.wikipedia.org). However, compliance with the EU's Falsified Medicines Directive remains imperative to ensure market access.
Alkem Laboratories Limited — Regulatory Compliance & Quality Standards
Regulatory compliance is paramount for sustaining export operations in stringent markets like the US and EU. Alkem's subsidiary, Enzene Biosciences, recently underwent a USFDA inspection at its Chakan facility, resulting in six procedural observations but no data integrity issues (m.economictimes.com). This outcome underscores the company's commitment to quality assurance and regulatory adherence. Continuous investment in compliance infrastructure and proactive engagement with regulatory bodies are essential for Alkem to navigate the evolving global regulatory landscape effectively.
About Alkem Laboratories Limited
Alkem Laboratories Limited exports 30 products worth $247.0M. Beyond Gliclazide, top products include Amlodipine, Cephalexin, Gabapentin, Ezetimibe, Mycophenolate. View the complete Alkem Laboratories Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Gliclazide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Gliclazide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Alkem Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 68 individual customs records matching Alkem Laboratories Limited exporting Gliclazide, covering 26 formulations to 2 countries via 5 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 109+ countries, 643+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Gliclazide Export Data from Alkem Laboratories Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Alkem Laboratories Limited's Gliclazide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Alkem Laboratories Limited
Full Company Profile →
30 products · $247.0M total trade · 15 categories
Gliclazide Stats
Company Overview
Top Products by Alkem Laboratories Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Alkem Laboratories Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Gliclazide. For current shipment-level data, contact TransData Nexus.